Other plasma cell disorders

P-420: Unusual Presentations of Amyloidosis: A Multicase Analysis Highlighting Diverse Clinical Manifestations and Diagnostic Challenges

P-423: Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study

P-424: Partial response or better at 6 months is not shown to be a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with acalabrutinib: A post hoc analysis

P-426: Thrombotic and bleeding complications in patients with AL amyloidosis

P-427: Smoldering multiple myeloma associated with a acquired von Willebrand syndrome , successfully treated by daratumumab, lenalidomide and dexamethasone

P-430: INCIDENCE OF PRIMARY PLASMA CELL LEUKEMIA WITH THE NEW DIAGNOSTIC CRITERIA.

P-431: Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia based on the revised criteria (KMM2204)

P-435: Acquired angioedema, a rare manifestation of MGCS

P-436: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Amyloid Light Chain (AL) Amyloidosis

P-437: Minor Salivary Gland Biopsy versus Bone Marrow Biopsy for the diagnosis of Amyloidosis AL: a comparative retrospective study

P-438: Castleman disease: histopathologic reclassification, clinical characteristics and endpoints in a reference center in Mexico

P-439: Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy

P-440: Validation of second revision of international staging system (R2 ISS) in a real-world myeloma population – an Asia Pacific Myeloma and Related Diseases Registry (APAC MRDR) study

P-444: A comparison of immunohistochemistry and laser microdissection tandem mass spectrometry to identify the amyloid fibril protein from formalin-fixed paraffin embedded biopsy samples.

P-445: Optimisation of laser capture microdissection with tandem mass spectrometry for the diagnosis of amyloid subtype.

P-446: Waldenström Macroglobulinaemia lymphoma patients have impaired platelet haemostatic function

P-447: Daratumumab based Induction for Plasma cell leukaemia & early ASCT: Experience from a tertiary care hospital in North India

P-448: Impact of Molecular Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas

P-499: DETECTION OF BENCE JONES PROTEINURIA BY SERUM FREE LIGHT CHAINS: DELIMITATION OF 24H URINE STUDIES IN PATIENTS WITH MONOCLONAL GAMMOPATHIES.

P-508: A Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma